Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Deferred Tax: 2023-2024

  • Eton Pharmaceuticals' Long-Term Deferred Tax rose 139.05% to $404,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $404,000, marking a year-over-year increase of 139.05%. This contributed to the annual value of $404,000 for FY2024, which is 139.05% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Long-Term Deferred Tax of $404,000 as of Q4 2024, which was up 139.05% from $169,000 recorded in Q4 2023.
  • In the past 5 years, Eton Pharmaceuticals' Long-Term Deferred Tax registered a high of $404,000 during Q4 2024, and its lowest value of $169,000 during Q4 2023.
  • For the 2-year period, Eton Pharmaceuticals' Long-Term Deferred Tax averaged around $286,500, with its median value being $286,500 (2023).
  • Data for Eton Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY skyrocketed of 139.05% (in 2024) over the last 5 years.
  • Over the past 2 years, Eton Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $169,000 in 2023, then surged by 139.05% to $404,000 in 2024.